Develops lorundrostat, an oral aldosterone synthase inhibitor, for treatment-resistant hypertension.
Develops lorundrostat, an oral aldosterone synthase inhibitor, for treatment-resistant hypertension.
Has no approved product and no sales; funding comes from raising capital, and everything rides on one drug, lorundrostat, through late-stage trials and regulatory review. Hypertension is dominated by cheap generics, so a new pill must earn its place with doctors and insurers.
Moat: none (IP / patents). Differentiated aldosterone synthase mechanism but competes directly with a similar AstraZeneca candidate.
Headquarters: Radnor, Pennsylvania, US · Founded: 2018 · Employees: 76
Size Mineralys Therapeutics (MLYS) is a United States Health Care company (Biotechnology) with a market value of $1.22B, the 2107th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.78 on 18 Nov 2026.
Performance Over six months the shares fell 51.5%, against -21.1% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 19 in its peer set.
Short interest Short interest is 8.7% of the free float (30 Oct 2026).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$30,000 | -$59,000 | -$43,000 | $0 | $0 |
| EBITDA | -$390M | -$171M | -$192M | -$84.7M | -$31.5M |
| Net income | -$370M | -$155M | -$178M | -$71.9M | -$29.8M |
| Free cash flow | -$153M | -$142M | -$166M | -$81.2M | -$29.2M |
| Capital expenditure | $15,000 | $15,000 | $96,000 | $0 | $0 |
| Total debt | $98.3M | $0 | $0 | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Mineralys Therapeutics MLYS | $1.22B | -52% | n/a | n/a | n/a | n/a |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 5.0× | 14.4% |
| Idorsia IDIA.SW | $1.22B | -9% | -5% | -70% | 10.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MLYS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -36.1% | -12.5% | 2nd lowest of 21 |
| 6-month return | -51.5% | -21.1% | 2nd lowest of 19 |
| Distance from 52-week high | -69.4% | -48.0% | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 2.2× | 6.6% | -7.0% |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 2.0× | 15.3% | +9.9% |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 3.5× | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 9.0× | 33.2% | -13.1% |
| Kardigan KARD | United States | $1.15B | n/a | n/a | n/a | n/a | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.15B | -25% | n/a | n/a | n/a | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | 170.1× | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 2.4× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | 164.8× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.36B | -23% | +36% | -4% | 6.8× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | 5.6× | n/a | n/a |